Predictive Technologies for Cell Line Development Enable Enhanced Manufacturability
To maximize success in biopharmaceutical clinical development and commercialization, incorporating strategies to optimize manufacturability early in development is essential. New technologies enable accurate prediction of bioreactor productivity, product quality, and cell line performance at the early stages of discovery and production cell line development. Implementation of such approaches will enable more efficient overall product development and will de-risk product supply to enable maximum market penetration. This talk will review current approaches to enhance product yield and quality from the bioreactor based on assessments of manufacturability at much smaller scales and much earlier timepoints during development.